趙春林 博士，安龍基金創(chuàng)始合伙人，安龍生物創(chuàng)始人，為清華大學生物系首屆畢業(yè)生，獲得美國匹茲堡醫(yī)學院分子生物學博士和芝加哥大學工商管理碩士，曾任美國輝瑞制藥資深經(jīng)理，國科嘉和及康橋資本董事總經(jīng)理，擁有三十多年生命科學及醫(yī)療健康領域的創(chuàng)業(yè)和投資經(jīng)驗，投資過信達生物，貝瑞合康，天鏡生物，歌禮藥業(yè)，萊凱醫(yī)藥，創(chuàng)響生物及國科恒泰等杰出企業(yè)。趙春林博士曾任清華大學生命科學院，醫(yī)學院及藥學院首屆校友會主席，為百華協(xié)會資深會員。 安龍基金是一只專注于國內早期生命科學與醫(yī)療健康領域的基金，投資領域橫跨生命科學，醫(yī)藥研發(fā)，醫(yī)療器械，醫(yī)療服務及相關領域。 安龍生物是國內核酸藥物領先企業(yè)，專注基因治療，RNA，基因編輯等核酸藥物的新藥研發(fā)。專業(yè)之外，趙春林博士喜歡足球，滑雪，曾做過DJ，擁有三個漂亮可愛的女兒。
Chunlin Zhao, Ph.D
Founder of the AnlongMed/AnlongBio. Dr. Zhao is among the first class graduated from Biological Science and Technology department at Tsinghua University in 1990. Then, he received his Ph.D of molecular biology at University of Pittsburgh School of Medicine and MBA from University of Chicago in the United States. Dr. Zhao was a senior manager at Pfizer in US. After returning to China, he founded Beijing LongMed biological technology co., LTD and then became partner of CASH Capital and C-Bridge Capital. Dr. Zhao has over 30 years of industry experience and excellent investment achievements, invested in Innovent, BerryGenomics, ASLETIS, GKHT and Imagine. Dr. Zhao is the founding Chairman of Tsinghua Alumni Association of School of Life Sciences，School of Medicine and School of Pharmaceutical Sciences, a senior member of BayHelix group. AnlongMed is a leading fund in Chinese life sciences and health care, focusing on biotech & pharma, medical devices, life sciences and medical services in China. Dr. Zhao also founded AnlongBio, a leading player in genetic medicine discovery in China, focusing on gene therapy, iRNA, mRNA, and other genetic medicines. Outside of his professional life, Dr. Zhao is a DJ, soccer player, ski lover, and has three lovely daughters.